First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate
Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate
Preliminary data from both trials on track for late-2023/early-2024 timeframe
Company to present and host investor meetings at Jefferies Healthcare Conference in NYC on June 7, 2023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.